Neil Bodick - Flexion Therapeutics Chief Medical Officer & Co-Founder

Founder

Dr. Neil Bodick, M.D., Ph.D. serves as Chief Scientific Officer of the Company. He is a cofounder and was appointed as our Chief Scientific Officer in April 2017, a role he transitioned to after serving as our Chief Medical Officer since our inception in 2007. Previously, Dr. Bodick was at Eli Lilly and Company, where he founded Chorus and served as Chief Medical Officer and Chief Operating Officer. Prior to that, Dr. Bodick was responsible for earlyphase clinical investigation at Lilly Research Laboratories. Dr. Bodick also was Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the development of computerbased systems to support image intensive diagnosis. Dr. Bodick holds 17 patents in the areas of musculoskeletal disorders, neuroscience and computer science and is the recipient of the Biomedical Research Service Award and the New Investigator Research Award from the National Institutes of Health since 2017.
Age 71
Tenure 7 years
Professional MarksMBA
Phone781 305-7777
Webwww.flexiontherapeutics.com
Bodick earned an A.B. from Cornell University, a Ph.D. in neuroscience from Columbia University, an M.D. from the Albert Einstein College of Medicine and an M.B.A. from the Wharton School of the University of Pennsylvania.

Flexion Therapeutics Management Efficiency

The company has return on total asset (ROA) of (18.99) % which means that it has lost $18.99 on every $100 spent on assets. This is way below average. Flexion Therapeutics' management efficiency ratios could be used to measure how well Flexion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 228.9 M in liabilities. Flexion Therapeutics has a current ratio of 4.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Flexion Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Flexion Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Flexion Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Flexion to invest in growth at high rates of return. When we think about Flexion Therapeutics' use of debt, we should always consider it together with cash and equity.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. Flexion Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 257 people. Flexion Therapeutics (FLXN) is traded on NASDAQ Exchange in USA and employs 257 people.

Management Performance

Flexion Therapeutics Leadership Team

Elected by the shareholders, the Flexion Therapeutics' board of directors comprises two types of representatives: Flexion Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Flexion. The board's role is to monitor Flexion Therapeutics' management team and ensure that shareholders' interests are well served. Flexion Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Flexion Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Arkowitz, CFO, Principal Financial Officer and Principal Accounting Officer
Sandesh Mahatme, Director
Scott Canute, Director
Mark Levine, Senior Vice President General Counsel, Secretary
Kerry Wentworth, Chief Regulatory Officer
Dan Thornton, Vice President - Market Access
John Magee, Vice President - Sales
Neil Bodick, Chief Medical Officer & Co-Founder
Mark Fraga, Vice President - Marketing
Michael Clayman, CEO, Co-Founder, Board Member
Ann Merrifield, Director
Alan Milinazzo, Independent Director
Jon Mahlowitz, VP of Legal Affairs
Frederick Driscoll, CFO and Principal Accounting Officer
Heath Lukatch, Independent Director
Christina Willwerth, Chief Strategy Officer
Patrick Mahaffy, Chairman of the Board
Samuel Colella, Independent Director
Yamo Deniz, Chief Medical Officer
Mark Stejbach, Director
Scott Kelley, Vice President - Medical Affairs

Flexion Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Flexion Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Consideration for investing in Flexion Stock

If you are still planning to invest in Flexion Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Flexion Therapeutics' history and understand the potential risks before investing.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges